No Data
No Data
EF Hutton Initiates Hoth Therapeutics(HOTH.US) With Buy Rating, Announces Target Price $5
Hoth Therapeutics Price Target Announced at $5.00/Share by EF Hutton
Hoth Therapeutics Coverage Assumed by EF Hutton at Buy
Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)
Express News | Hoth Therapeutics Aronnax Enter Master Services Agreement For HT-KIT Cancer Therapeutic
Express News | Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement for Ht-Kit Cancer Therapeutic
No Data